OssDsign reaches commercial milestone of 750 implants sold in Germany
Uppsala, April 27, 2023. OssDsign AB (publ.) today announces that the company has reached the commercial milestone of 750 implants sold in Germany since market entry, with a significant acceleration in sales during the last two years.
Germany is one of the most important markets in Europe and, in recent years, OssDsign has considerably increased its sales efforts in Germany, resulting in a significant acceleration in sales. In addition to this, the company has successfully delivered on its strategic priority to increase operational efficiency and reduce lead time for OssDsign Cranial PSI.
”It is evident and very rewarding that our strategic changes have considerably accelerated the sales growth in Germany, resulting in this great achievement. Our recent optimizations in manufacturing that reduces the lead time of OssDsign Cranial PSI will further strengthen our product offering and help accelerate growth going forward,” said Morten Henneveld, CEO, OssDsign.
OssDsign Cranial PSI is a patient-specific cranial implant made from 3D printed medical-grade titanium covered by a regenerative calcium phosphate composition. While the titanium skeleton reinforces the implant and resists physical and mechanical stress, the unique calcium phosphate composition provides healing and regenerative properties, allowing regrowth of the patient's own bone. Over time, the calcium phosphate composition degrades and is replaced with bone, leaving the patient with a well-integrated implant, potentially lasting a lifetime.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: [email protected]
Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: [email protected]
About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give back patients the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
